| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| ATAZANAVIR
| ATAZANAVIR |
ANTIINFECTIVES | ORAL | Cmax 8.7 MICROMOLAR Tmax 2.5 HOUR PPB 86 PERCENT HT 7.9 HOUR SOLUBILITY SLIGHTLY SOLUBLE IN WATER 4 TO 5 MILLIGRAM / MILLILITER WITH THE PH=1.9 AT 24 DEGREE CELSIUS | HIV-1 PROTEASE PDB 3EKW (CRYSTAL STRUCTURE OF THE INHIBITOR ATAZANAVIR (ATV) IN COMPLEX WITH A MULTI-DRUG RESISTANCE HIV-1 PROTEASE VARIANT (L10I/G48V/I54V/V64I/V82A) REFER: FLAP+ IN CITATION.) LIGAND CODE = DR7 (link to the list of PDB complexes) Download experimental 3D coordinates of DR7 with added hydrogens | HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE INHIBITOR CHEMBL243 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE Q72874 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS 1 ENZYME PROTEASE ASPARTIC AA A2A | EMA | |||
